β-Blockers and the Risk of Depression: A Matched Case-Control Study.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
02 2022
Historique:
accepted: 16 12 2021
pubmed: 20 1 2022
medline: 22 4 2022
entrez: 19 1 2022
Statut: ppublish

Résumé

Depression is a commonly cited adverse effect of β-blockers but the evidence for a causal relationship is limited. We aimed to explore whether β-blockers are associated with an increased risk of new-onset depression. We conducted a case-control study using the UK population-based Clinical Practice Research Datalink (CPRD) GOLD. We identified patients aged 18-80 years with an incident depression diagnosis between 2000 and 2016, and matched controls, and estimated the risk (odds ratio [OR]) of depression in association with use of β-blockers. We also conducted analyses of exposure, categorised by number and timing of prescriptions and by indication for β-blocker use. The study encompassed 118,705 patients with incident depression and the same number of matched controls. The odds of developing depression were increased for current short-term use of any β-blocker (adjusted OR [aOR] 1.91, 95% confidence interval [CI] 1.72-2.12), whereas current long-term use was not associated with the risk of depression compared with never use. The elevated risk of depression among short-term users was mostly confined to propranolol users with a neuropsychiatric disorder (aOR 6.33, 95% CI 5.16-7.76), while propranolol users with a cardiovascular indication were only at marginally increased risk of depression (aOR 1.44, 95% CI 1.14-1.82). This study suggests that the association between use of β-blockers and depression may not be causal but rather a result of protopathic bias. Propranolol is often prescribed to treat neuropsychiatric symptoms, suggesting that the onset of depression may be related to the underlying indication rather than to an effect of a β-blocker therapy.

Identifiants

pubmed: 35044637
doi: 10.1007/s40264-021-01140-5
pii: 10.1007/s40264-021-01140-5
pmc: PMC8857000
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Propranolol 9Y8NXQ24VQ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-189

Informations de copyright

© 2022. The Author(s).

Références

National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management: NICE guideline [NG106]. 2018. https://www.nice.org.uk/guidance/ng106 . Accessed 21 Jul 2019.
Montalescot G, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. https://doi.org/10.1093/eurheartj/eht296 .
doi: 10.1093/eurheartj/eht296 pubmed: 23996286
National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management: NICE guideline [NG196]. 2021. https://www.nice.org.uk/guidance/ng196 . Accessed 19 Nov 2021.
Mancia G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. https://doi.org/10.1093/eurheartj/eht151 .
doi: 10.1093/eurheartj/eht151 pubmed: 23771844
Kiel RG, Deedwania P. The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified? Expert Opin Drug Saf. 2015;14(12):1855–63. https://doi.org/10.1517/14740338.2015.1102225 .
doi: 10.1517/14740338.2015.1102225 pubmed: 26488593
Verbeek DE, et al. A review on the putative association between beta-blockers and depression. Heart Fail Clin. 2011;7(1):89–99. https://doi.org/10.1016/j.hfc.2010.08.006 .
doi: 10.1016/j.hfc.2010.08.006 pubmed: 21109212
Stoschitzky K, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55(2):111–5.
doi: 10.1007/s002280050604
Poirier L, Tobe SW. Contemporary use of beta-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9–15. https://doi.org/10.1016/j.cjca.2013.12.001 .
doi: 10.1016/j.cjca.2013.12.001 pubmed: 24684855
Frishman WH. The beta-adrenoceptor blocking drugs. Int J Cardiol. 1982;2(2):165–78.
doi: 10.1016/0167-5273(82)90031-6
Oppenheim G. Propranolol-induced depression: mechanism and management. Aust N Z J Psychiatry. 1983;17(4):400–2. https://doi.org/10.1080/00048678309160022 .
doi: 10.1080/00048678309160022 pubmed: 6581802
Waal HJ. Propranolol-induced depression. Br Med J. 1967;2(5543):50.
doi: 10.1136/bmj.2.5543.50
Nolan BT. Acute suicidal depression associated with use of timolol. JAMA. 1982;247(11):1567.
doi: 10.1001/jama.1982.03320360019022
Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA. 1986;255(3):357–60.
doi: 10.1001/jama.1986.03370030077031
Thiessen BQ, et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med. 1990;150(11):2286–90.
doi: 10.1001/archinte.1990.00390220044009
Johnell K, Fastbom J. The association between use of cardiovascular drugs and antidepressants: a nationwide register-based study. Eur J Clin Pharmacol. 2008;64(11):1119–24. https://doi.org/10.1007/s00228-008-0541-3 .
doi: 10.1007/s00228-008-0541-3 pubmed: 18685838
van Melle JP, et al. Treatment of depression in acute coronary syndromes with selective serotonin reuptake inhibitors. Drugs. 2006;66(16):2095–107.
doi: 10.2165/00003495-200666160-00005
van Melle JP, et al. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol. 2006;48(11):2209–14. https://doi.org/10.1016/j.jacc.2006.07.056 .
doi: 10.1016/j.jacc.2006.07.056 pubmed: 17161247
Kessing LV, et al. Antihypertensive drugs and risk of depression: a nationwide population-based study. Hypertension. 2020;76(4):1263–79. https://doi.org/10.1161/HYPERTENSIONAHA.120.15605 .
doi: 10.1161/HYPERTENSIONAHA.120.15605 pubmed: 32829669
Riemer TG, et al. Do beta-Blockers Cause Depression? Systematic review and meta-analysis of psychiatric adverse events during beta-blocker therapy. Hypertension. 2021;77(5):1539–48. https://doi.org/10.1161/HYPERTENSIONAHA.120.16590 .
doi: 10.1161/HYPERTENSIONAHA.120.16590 pubmed: 33719510
Herrett E, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36. https://doi.org/10.1093/ije/dyv098 .
doi: 10.1093/ije/dyv098 pubmed: 4521131 pmcid: 4521131
Wolf A, et al. Data resource profile: clinical practice research datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740–1740g. https://doi.org/10.1093/ije/dyz034 .
doi: 10.1093/ije/dyz034 pubmed: 30859197 pmcid: 6929522
Herrett E, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. https://doi.org/10.1111/j.1365-2125.2009.03537.x .
doi: 10.1111/j.1365-2125.2009.03537.x pubmed: 20078607 pmcid: 2805870
John A, et al. Case-finding for common mental disorders of anxiety and depression in primary care: an external validation of routinely collected data. BMC Med Inform Decis Mak. 2016;16:35. https://doi.org/10.1186/s12911-016-0274-7 .
doi: 10.1186/s12911-016-0274-7 pubmed: 26979325 pmcid: 4791907
Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry. 1990;35(3):257–9.
doi: 10.1177/070674379003500312
Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry. 1996;29(6):201–11. https://doi.org/10.1055/s-2007-979572 .
doi: 10.1055/s-2007-979572 pubmed: 8956349
Ko DT, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–7.
doi: 10.1001/jama.288.3.351
Luijendijk HJ, et al. Beta-blockers and the risk of incident depression in the elderly. J Clin Psychopharmacol. 2011;31(1):45–50. https://doi.org/10.1097/JCP.0b013e31820482c4 .
doi: 10.1097/JCP.0b013e31820482c4 pubmed: 21192142
Thapar A, et al. Depression in adolescence. Lancet. 2012;379(9820):1056–67. https://doi.org/10.1016/S0140-6736(11)60871-4 .
doi: 10.1016/S0140-6736(11)60871-4 pubmed: 22305766 pmcid: 3488279

Auteurs

Delia Bornand (D)

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Spitalstrasse 26, 4031, Switzerland.
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

Daphne Reinau (D)

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Spitalstrasse 26, 4031, Switzerland.
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

Susan S Jick (SS)

Boston Collaborative Drug Surveillance Program, Lexington, MA, USA.
School of Public Health, Boston University, Lexington, MA, USA.

Christoph R Meier (CR)

Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Spitalstrasse 26, 4031, Switzerland. christoph.meier@usb.ch.
Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. christoph.meier@usb.ch.
Boston Collaborative Drug Surveillance Program, Lexington, MA, USA. christoph.meier@usb.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH